Compare Pfizer Inc (PFE) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Uranium Energy Corp — how do they compare? Pfizer Inc trades at $27.66 (market cap $158.34B), while Uranium Energy Corp trades at $11.63 (market cap $5.74B). The key difference: Pfizer Inc is far larger — about 27.6× Uranium Energy Corp's market cap, and Pfizer Inc pays a 6.19% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| PFE | UEC | |
|---|---|---|
Market Cap | $158.34B | $5.74B |
Volume | 29,869,932 | — |
Sector | Health | Energy |
52-Week High | $29.02 | $20.14 |
52-Week Low | $23.60 | $9.04 |
Enterprise Value | $209.83B | $5.25B |
Dividend Yield | 6.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
UEC is trading at $11.89, up 3.03% today, with a bullish technical signal despite negative profitability metrics. The company reported a net loss of $87.66 million in 2025 with revenue of $66.84 million, though it beat Q4 2025 EPS expectations. Analyst sentiment remains strongly positive with 87.5% buy ratings, supported by institutional interest including BlackRock's recent $432.68 million investment.
The outlook for UEC is mixed, with strong analyst support and nuclear energy tailwinds offset by persistent losses and negative margins. Key risks include execution challenges and uranium price volatility, while opportunities lie in the growing nuclear power sector and institutional backing. The stock trades near recent support levels with technical indicators suggesting potential near-term strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
